← Back to Search

Other

BMS-986179 for Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first measure response approximately up to 25 months
Awards & highlights

Summary

This study is evaluating whether a new drug can shrink tumors in people with cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first measure response approximately up to 25 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first measure response approximately up to 25 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Drug Related AEs, SAEs, AEs Leading to Discontinuation and Deaths.
Secondary outcome measures
AUC (0-T)
AUC (Tau)
Cmax
+8 more

Side effects data

From 2021 Phase 1 & 2 trial • 235 Patients • NCT02754141
100%
Lymphocyte count decreased
100%
Blood creatinine increased
100%
Back pain
100%
Anaemia
100%
Red blood cell count decreased
100%
Hyperglycaemia
100%
Pain in extremity
100%
Chromaturia
100%
Immature granulocyte count increased
100%
Arthralgia
100%
Hypertension
100%
Haematuria
100%
Constipation
100%
Oedema peripheral
100%
Glomerular filtration rate decreased
100%
Lipase increased
100%
White blood cell count increased
100%
Neutrophil count increased
100%
Paraesthesia
100%
80%
60%
40%
20%
0%
Study treatment Arm
P2 Monotherapy Unassigned
P2 Combo NSCLC
P2 Combo Melanoma
P2 Combo SCCHN
P2 RCC Combo
P2 Combo Unassigned
P2 RCC Mono
P2 Combo Prostate
P2 RCC Crossover
P2 All Combo Therapy
ALL Combo (P1A+P1B+P2)
P1B BMS-986179 1600mg
P1A 150mg
P1A 300mg
P1A 600mg
P1A 1200mg
P1A 1600mg
P1A All Mono
P1A Combo Therapy 150mg
P1A Combo Therapy 300mg
P1A Combo Therapy 600mg
P1A Combo Therapy 1200mg
P1A Combo Therapy 1600mg
P1A All Combo
P1B Combo Therapy 150mg
P1B Combo Therapy BMS-986179 1200mg + Nivo360mg
P1B Combo Therapy BMS-986179 1200mg + Nivo 480mg
P1B All Combo
P2 Combo Pancreatic

Trial Design

3Treatment groups
Experimental Treatment
Group I: Arm C-Combination TherapyExperimental Treatment2 Interventions
BMS-986179 + rHuPH20, dose as specified
Group II: Arm B- Combination TherapyExperimental Treatment2 Interventions
BMS-986179 + nivolumab, dose as specified
Group III: Arm A-MonotherapyExperimental Treatment1 Intervention
BMS-986179, dose as specified
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986179
2016
Completed Phase 2
~240
Nivolumab
2014
Completed Phase 3
~4740
rHuPH20
2008
Completed Phase 2
~650

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,652 Previous Clinical Trials
4,130,514 Total Patients Enrolled
~26 spots leftby Jul 2025